The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02902380

Enrollment

Registered

2016-09-15

Start date

2016-09-27

Completion date

2017-07-01

Last updated

2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Stenosis

Brief summary

Surgical stress induces stress hormone release and sympathetic hyperactivation. Dexmedetomidine has sympatholytic effect and attenuates stress responses. This study investigate the effect of dexmedetomidine on stress responses and autonomic nervous system balance in patients undergoing major spine surgery.

Interventions

DRUGdexmedetomidine group

dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery

DRUGcontrol group

0.9% saline infusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ * patient scheduled for major spine surgery

Exclusion criteria

* ASA physical status Ⅳ * congestive heart failure * severe hepatorenal disease * insulin dependent DM(diabetes mellitus) * cancer or metastasis * pregnancy * problem with communication

Design outcomes

Primary

Measure	Time frame	Description
Stress hormone level	immediately after anesthetic induction	The levels of stress hormone including epinephrine, norepinephrine, cortisol, and glucose will be measured during spinal surgery.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026